CW July 2004
Volume 13Issue Number 7 July 2004 ISSN 10593802 Watch for Fracture Risk in Prostate CancerWidely used androgen-deprivation therapy (ADT) increases the risk of fractures by 40% in men with non-metastatic prostate cancer, according to an analysis of Medicare claims data of more than 11,000 men. Bone mineral density (BMD) measurements can assess when to intervene with intravenous bisphosphonates, the most potent being zoledronic acid (Zometa).
Go to Previous Page Source & Additional Reading Matthew Smith, assistant professor of medicine at Harvard. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
